tetano
Editor, Senior Moderator
J Fungi (Basel)
. 2022 Mar 24;8(4):339.
doi: 10.3390/jof8040339.
Association of Tocilizumab and Invasive Aspergillosis in Critically Ill Patients with Severe COVID-19 Pneumonia and Acute Respiratory Distress Syndrome
Kuo-Lun Wu[SUP] 1 [/SUP], Chia-Yuan Chang[SUP] 2 [/SUP], Heng-You Sung[SUP] 2 [/SUP], Ting-Yu Hu[SUP] 3 4 [/SUP], Li-Kuo Kuo[SUP] 3 4 [/SUP]
Affiliations
Abstract
Coronavirus disease-2019 (COVID-19) causes severe pneumonia and acute respiratory distress syndrome. According to the current consensus, immunosuppressants, such as dexamethasone and anti-interleukin-6 receptor monoclonal antibodies, are therapeutic medications in the early stages of infection. However, in critically ill patients, viral, fungal, and bacterial coinfection results in higher mortality. We conducted a single-center, retrospective analysis of 29 mechanically ventilated patients with artificial airways. Patients were adults with confirmed COVID-19 infection and severe pneumonia. Acute respiratory distress syndrome was diagnosed according to the Kigali modification of the Berlin definition. Six patients had invasive pulmonary aspergillosis coinfection based on elevated serum galactomannan levels and/or bronchoalveolar lavage fluid. We present two cases with brief histories and available clinical data. We also conducted a literature review to determine whether immunosuppressants, such as tocilizumab, increase infection risk or invasive aspergillosis in patients with COVID-19. There is no conclusive evidence to suggest that tocilizumab increases coinfection risk. However, further studies are needed to determine the optimal dose, between-dose interval, and timing of tocilizumab administration in patients with COVID-19.
Keywords: COVID-19-associated pulmonary aspergillosis; acute respiratory distress syndrome; tocilizumab.
. 2022 Mar 24;8(4):339.
doi: 10.3390/jof8040339.
Association of Tocilizumab and Invasive Aspergillosis in Critically Ill Patients with Severe COVID-19 Pneumonia and Acute Respiratory Distress Syndrome
Kuo-Lun Wu[SUP] 1 [/SUP], Chia-Yuan Chang[SUP] 2 [/SUP], Heng-You Sung[SUP] 2 [/SUP], Ting-Yu Hu[SUP] 3 4 [/SUP], Li-Kuo Kuo[SUP] 3 4 [/SUP]
Affiliations
- PMID: 35448570
- DOI: 10.3390/jof8040339
Abstract
Coronavirus disease-2019 (COVID-19) causes severe pneumonia and acute respiratory distress syndrome. According to the current consensus, immunosuppressants, such as dexamethasone and anti-interleukin-6 receptor monoclonal antibodies, are therapeutic medications in the early stages of infection. However, in critically ill patients, viral, fungal, and bacterial coinfection results in higher mortality. We conducted a single-center, retrospective analysis of 29 mechanically ventilated patients with artificial airways. Patients were adults with confirmed COVID-19 infection and severe pneumonia. Acute respiratory distress syndrome was diagnosed according to the Kigali modification of the Berlin definition. Six patients had invasive pulmonary aspergillosis coinfection based on elevated serum galactomannan levels and/or bronchoalveolar lavage fluid. We present two cases with brief histories and available clinical data. We also conducted a literature review to determine whether immunosuppressants, such as tocilizumab, increase infection risk or invasive aspergillosis in patients with COVID-19. There is no conclusive evidence to suggest that tocilizumab increases coinfection risk. However, further studies are needed to determine the optimal dose, between-dose interval, and timing of tocilizumab administration in patients with COVID-19.
Keywords: COVID-19-associated pulmonary aspergillosis; acute respiratory distress syndrome; tocilizumab.